Register entry
OPELLA HEALTHCARE INTERNATIONAL SAS
Data as of · How to read this entry
- Registered sites
- 1
- Active NDC listings
- 17
- Live patents
- 0
- Countries
- 1
- Base
- France
Authorisation
Registered operations
Analytical testing1Labelling1Finished drug manufacture1Packaging1Relabelling1Repackaging1
Sites
Registered establishments
1| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| OPELLA HEALTHCARE INTERNATIONAL SAS | 56 Route de Choisy, Compiegne, 60200, France (FRA) | Analytical testing, Labelling, Finished drug manufacture, Packaging, Relabelling, Repackaging | 3003492806275857012 |
Catalogue
Drug listings by form and route
1717 active NDC listings: 15 drug for further processing, 2 bulk ingredient. By marketing category: DRUG FOR FURTHER PROCESSING 15, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING 2.
| Dosage form | NDCs |
|---|---|
| tablet, film coated | 6 |
| tablet | 4 |
| tablet, coated | 3 |
| tablet, film coated, extended release | 3 |
| tablet, orally disintegrating | 1 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| opella healthcare international sas | 17 |
Catalogue
Marketed products
17| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | FEXOFENADINE HYDROCHLORIDE | tablet, film coated, extended release | 12579-182DRUG FOR FURTHER PROCESSING |
| - | FEXOFENADINE HYDROCHLORIDE | tablet, film coated, extended release | 12579-189DRUG FOR FURTHER PROCESSING |
| - | Fexofenadine Hydrochloride | tablet, orally disintegrating | 12579-188DRUG FOR FURTHER PROCESSING |
| - | LEVOCETIRIZINE DIHYDROCHLORIDE | tablet | 12579-180DRUG FOR FURTHER PROCESSING |
| - | Tadalafil | tablet, coated | 12579-200DRUG FOR FURTHER PROCESSING |
| - | bisacodyl | tablet, coated | 12579-228DRUG FOR FURTHER PROCESSING |
| - | bisacodyl | tablet, coated | 12579-230DRUG FOR FURTHER PROCESSING |
| - | fexofenadine hydrochloride | tablet, film coated, extended release | 12579-181DRUG FOR FURTHER PROCESSING |
| - | glyburide | tablet | 12579-054DRUG FOR FURTHER PROCESSING |
| - | glyburide | tablet | 12579-055DRUG FOR FURTHER PROCESSING |
| - | glyburide | tablet | 12579-056DRUG FOR FURTHER PROCESSING |
| - | leflunomide | tablet, film coated | 12579-509BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | leflunomide | tablet, film coated | 12579-510BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | teriflunomide | tablet, film coated | 12579-185DRUG FOR FURTHER PROCESSING |
| - | teriflunomide | tablet, film coated | 12579-186DRUG FOR FURTHER PROCESSING |
| - | teriflunomide | tablet, film coated | 12579-190DRUG FOR FURTHER PROCESSING |
| - | teriflunomide | tablet, film coated | 12579-191DRUG FOR FURTHER PROCESSING |
Neighbours
Registered in the same town
1- Chanel, Inc.Compiegne, FRA
Compare
Comparable companies in France
- Parfums Christian Dior1 site · 224 NDC
- Sevene SAS1 site · 154 NDC
- BCM Cosmetique1 site · 72 NDC
- Recordati Rare Diseases1 site · 21 NDC
- Guerlain1 site · 18 NDC
- Valdepharm1 site · 17 NDC
- Septodont SAS1 site · 15 NDC
- Laboratoires Clarins1 site · 14 NDC
- Meribel Pharma Pessac1 site · 8 NDC
- C.F.E.B. - Sisley1 site · 7 NDC
Enquiry
Common questions
- Is OPELLA HEALTHCARE INTERNATIONAL SAS FDA approved?
- OPELLA HEALTHCARE INTERNATIONAL SAS holds 1 FDA-registered establishment in France. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are OPELLA HEALTHCARE INTERNATIONAL SAS's drugs manufactured?
- The FDA register lists Compiegne. Registered operations: analytical testing, labelling, finished drug manufacture, packaging, relabelling, repackaging.
- What drugs does OPELLA HEALTHCARE INTERNATIONAL SAS make?
- 17 products are listed under OPELLA HEALTHCARE INTERNATIONAL SAS in the openFDA NDC Directory, most often as tablet, film coated; tablet; tablet, coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.